CheckMate914

CheckMate 914 Archives

IJMS, Free Full-Text

Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, KEYNOTE-991

CHECKMATE-914 Phase 3 Kidney Cancer Trial [2022]

Adjuvant immunotherapy does not improve DFS in renal cancer

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

From neoadjuvant to second-line therapeutic options for RCC patients

EIKCS 2022: Selecting Renal Cell Carcinoma Patients for Adjuvant Therapy

Adjuvant Immunotherapy in Resected Renal Cell Carcinoma: Déjà vu or Progress?

BMS joins Roche on the adjuvant kidney cancer flop list

Checkpoint inhibitor immunotherapy in kidney cancer